Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole

References

• Pang KR, Wu JJ, Huang DB, Tyring S. Subcutaneous fungal infections. Dermatol Ther 2004; 17: 523–531
   PubMedGoogle Scholar
• McGinnis MR. Chromoblastomycosis and phaeohyphomycosis. New concepts, diagnosis, and mycology. J Am Acad Dermatol 1983; 8: 1–16
   PubMed Web of Science ®Google Scholar
• De Hoog GS, Atilli-Angelis D, Vicente VA, et al. Molecular ecology and pathogenic potencial of Fosecaea species. Med Mycol 2004; 42: 406–416
   Google Scholar
• Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin N Am 2003; 17: 59–85
   PubMed Web of Science ®Google Scholar
• Padhye AA, Hampton AA, Hampton MT, et al. Chromoblastomycosis caused by Exophiala spinifera. Clin Infect Dis 1996; 22: 331–335
   PubMed Web of Science ®Google Scholar
• Rivitti EA, Aoki V. Deep fungal infections in tropical countries. Clin Dermatol 1999; 17: 171–190
   PubMed Web of Science ®Google Scholar
• Yegres, JF, De Yegres, NR, Perez Blanco, M. Cromomicosis. In: MC Bastardo De Albornoz. Temas de Micologia Medica, 1st edn. Caracas, Venezuela: Litografia y Tipografia ELALCA s.r.l., 1996: 87–102.
   Google Scholar
• Queiroz-Telles F, Purin K, Fillus JN. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol 1992; 31: 805–812
   PubMed Web of Science ®Google Scholar
• Bayles M. Tropical mycoses. Chemotherapy 1992; 38: 27–34
   Google Scholar
• Park SG, Oh SH, Suh SB, et al. A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: Treatment with a combination of amphotericin B and 5-flucytosine. Br J Dermatol 2005; 152: 560–564
   Google Scholar
• Kinbara T, Fukushiro R, Eryu Y. Chromomycosis: Report of two cases successfully treated with topical heat therapy. Mykosen 1982; 25: 689–694
   PubMedGoogle Scholar
• Tagami H, Ginoza M, Imaizumi S. Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol 1984; 10: 615–619
   PubMed Web of Science ®Google Scholar
• Yanase K, Yamada M. Pocket-warmer therapy of chromomycosis. Arch Dermatol 1978; 114: 1095
   PubMedGoogle Scholar
• Bonifaz A, Paredes-Solís V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother 2004; 5: 247–254
   PubMed Web of Science ®Google Scholar
• Tanuma H, Hiramutsu M, Mukai H, et al. Case report: A case of chromoblastomycosis effectively treated with terbinafine. Mycoses 1999; 43: 79–83
   Google Scholar
• Pérez-Blanco M, Hernández Valles R, Fernández Zeppenfeldt G, et al. Ajoene and 5-fluorouacil in the topical treatment of Cladophialophora carrionii chromoblastomycosis in humans: A comparative open study. Med Mycol 2003; 41: 517–520
   PubMed Web of Science ®Google Scholar
• Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987; 9: S57–63
   Google Scholar
• Bopp C. Cura da cromoblastomicose por novo tratamento. Med Cut ILA 1976; 4: 285–292
   Google Scholar
• Astorga E, Bonilla E, Martinez C, et al. Tratamiento de la cromoblastomicosis com la anfotericina-B y 5-fluorcitosina. Med Cut ILA 1981; IX: 125–128
   Google Scholar
• Cucé LC, Wroclawski EL, Sampaio SAP. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis and mycetoma with ketoconazole. Int J Dermatol 1980; 19: 405–408
   PubMed Web of Science ®Google Scholar
• Kumar B, Kaur I, Chaklraberti A, et al. Treatment of deep mycosis with itraconazole. Mycopathologia 1991; 115: 169–174
   PubMedGoogle Scholar
• Ungpakron R, Reangchainam S. Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis. Clin Exp Dermatol 2006; 31: 245–247
   Google Scholar
• Restrepo A, Gonzalez A, Gomez I, et al. Treatment of chromoblastomycosis with itraconazole. Ann NY Acad Sci 1998; 544: 504–516
   Google Scholar
• Franco I, Gomes I, Restrepo A. Saperconazole in the treatment in systemic and subcutaneous mycosis. Int J Dermatol 1992; 31: 725–729
   PubMedGoogle Scholar
• Cardona-Castro N, Agudelo-Florez P, Restrepo-Molina R. Chromoblastomycosis murine model and in vitro test to evaluate the sensitivity of Fonsecaea pedrosoi to ketoconazole, itraconazole and saperconazole. Mem Inst Oswaldo Cruz 1996; 91: 779–784
   PubMed Web of Science ®Google Scholar
• Valle AC, Wanke B, Lazera MS, et al. Entomophtothoramycosis by Conidiobolus coronatus. Report of a case successfully treated with the combination of itraconazole and fluconazole. Rev Inst Med Trop Sao Paulo 2001; 43: 233–236
   Google Scholar
• Herbrecht R. Posaconazole: A potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58: 612–624
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775–785
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–2956
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer AF, et al. Antifungal activity of a new triazole, voriconazole (UK-109,496) compared with three other antifungal agents against clinical isolates of filamentous fungi. Med Mycol 1998; 36: 433–461
   PubMed Web of Science ®Google Scholar
• Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005; 47: 339–346
   PubMedGoogle Scholar
• Paugam A. The latest data on posaconazole. Med Mal Infect 2007; 37: 71–76
   PubMedGoogle Scholar
• McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58: 179–202
   PubMed Web of Science ®Google Scholar
• Loo DS. Systemic antifungal agents: An update of established and new therapies. Adv Dermatol 2006; 22: 101–124
   PubMedGoogle Scholar
• Esterre P, Inzan CK, Ramarcel ER. Treatment of chromoblastomycosis with terbinafine: Preliminary results of an open pilot study. Br J Dermatol 2001; 134: 33–36
   Google Scholar
• Sevigny GM, Ramos-Caro FA. Treatment of chromoblastomycosis due to Fonsecaea pedrosoi with low-dose terbinafine. Cutis 2000; 66: 45–46
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Martínez-Soto E, Carrasco-Gerard E, et al. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol 1997; 36: 542–547
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: Clinical and mycologic experience of 51 cases. Mycoses 2001; 44: 1–7
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002; 40: 529–534
   PubMed Web of Science ®Google Scholar
• Andrade TS, Castro LG, Nunes RS, et al. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 2004; 47: 216–221
   PubMed Web of Science ®Google Scholar
• Hardman JG, Limbird LE. Antimicrobial agents: Antifungal agents. Goodman and Gilman's: The Pharmacological Basis of Therapeutics9^th edn, JG Hardman, AG Gilman, LE Limbird. McGraw-Hill, New York 1996; 1175–1190
   Google Scholar
• Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272–279
   PubMed Web of Science ®Google Scholar